Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus حسب Dimitrios, Patoulias

"…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …"
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل

Mobility Competitiveness and Security: Expatriate Perspectives from Qatar حسب Ewers, Michael Christopher

احصل على النص الكامل
احصل على النص الكامل